Trial · NCT06926920
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920, Phase 1, Phase 2, Recruiting, Gilead Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer. Trials, record NCT06926920. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06926920
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- NCT number
- NCT06926920
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Gilead Sciences
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Sacituzumab Govitecan-hziy (SG)
- First posted
- 2025-04-15
- Last updated
- 2026-01-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs) | First dose up to 28 days | |
| Primary | Phase 1 and 2: Percentages of Participants Experiencing Adverse Events (AEs) | First dose up to 30 days post last dose (Up to 3 years) | |
| Primary | Phases 1 and 2: Percentages of Participants Experiencing Laboratory Abnormalities | First dose up to 30 days post last dose (Up to 3 years). | |
| Primary | Phases 1 and 2: Percentages of Participants Experiencing AEs Leading to Dose Reductions, Dose Interruptions, and Treatment Discontinuations | First dose up to 30 days post last dose (Up to 3 years). | |
| Primary | Phases 1 and 2: Objective Response Rate (ORR) | Up to 9 months | ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. |
| Primary | Phase 2: Progression-Free Survival (PFS) | Up to 9 months | PFS is defined as the time from the date of the first SG dose until the date of progressive disease (PD) as assessed by the investigator according to RECIST Version 1.1, or death from any cause, whichever occurs first. |
| Secondary | Phases 1 and 2: Serum Concentrations of SG | Up to End of Treatment (3 years) | |
| Secondary | Phase 1 and 2: Percentage of Participants who Develop Antidrug Antibodies (ADAs) Against SG | First dose up to 30 days post last dose (Up to 3 years). | |
| Secondary | Phase 2: Duration of Response (DOR) | First dose up to 30 days post last dose (Up to 3 years). | DOR is defined as the time from the first documentation of CR or PR to the first documentation of PD as assessed by the investigator according to RECIST Version 1.1, or death from any cause, whichever occurs first. |
| Secondary | Phase 2: Disease Control Rate (DCR) | Up to 9 months | DCR is defined as the proportion of participants who achieve CR, PR, or stable disease as assessed by the investigator according to RECIST Version 1.1. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06926920
GET https://conductscience.org/api/trials/v1/NCT06926920/registered